Tizanidine intranasal - MDM SpA

Drug Profile

Tizanidine intranasal - MDM SpA

Alternative Names: Tizanidine nasal spray - MDM SpA; Tizaspray

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MDM SpA
  • Class Antispastics; Benzothiazoles; Imidazolidines; Imidazolines; Muscle relaxants; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Back pain

Most Recent Events

  • 05 Sep 2017 Tizanidine intranasal is still in phase III development for Back pain in Italy (NCT02934061) (EudraCT2014-003040-12)
  • 01 Feb 2017 MDM SpA completes a phase III trial in Back pain in Italy (Intranasal) (NCT02934061)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top